comparemela.com

Latest Breaking News On - University hospital arnau de vilanova - Page 1 : comparemela.com

Trastuzumab Plus Pertuzumab Provides Sustained iDFS Benefit in HER2+ Breast Cancer

A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.

Valencia
Carabobo
Venezuela
Spain
Antonio-llombart-cussac
University-hospital-arnau-de-vilanova
Oncology-service
Medical-oncology-service
Her2-positive-early-breast-cancer
Chemotherapy-free-regimen
Btrastuzumab
Pertuzumab

Early progression on CDK4/6 regimen a 'strong' predictor of OS in breast cancer subset

Early progression on CDK4/6 regimen a 'strong' predictor of OS in breast cancer subset
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

San-antonio
Texas
United-states
Spain
Bymatthew-shinkle
Mindy-valcarcel
Antonio-llombart-cussac
Pfizer
University-hospital-arnau-de-vilanova
San-antonio-breast-cancer
San-antonio-breast-cancer-symposium
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.